Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium - Comparison of clinico-pathological and survival outcomes

被引：0
|
作者：
Genova, L. [1 ]
Andreasi, V [1 ]
Partelli, S. [1 ]
Muffatti, F. [1 ]
Battistella, A. [1 ]
Crippa, S. [1 ]
Tamburrino, D. [1 ]
Pecorelli, N. [1 ]
Balzano, G. [1 ]
Falconi, M. [1 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Italy
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷
关键词：
peptide receptor radionuclide therapy; prrt; neoadjuvant; surgery; yttrium; lutetium;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H15
引用
收藏
页码：187 / 187
页数：1
相关论文
共 41 条
  • [1] Peptide receptor radionuclide therapy (PRRT) of metastatic thyroid cancer using yttrium-90 and lutetium-177 labelled somatostatin analogues: Preliminary results
    Mundschenk, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S240 - S240
  • [2] Preliminary dosimetric study with 177-Lutetium Peptide Receptor Radionuclide Therapy for Pediatric Patients with neuroendocrine tumors
    Cassano, B.
    Genovese, E.
    Polito, C.
    Longo, M.
    Donatiello, S.
    Napolitano, A.
    Insero, T.
    Valeri, S.
    Pizzoferro, M.
    Serra, A.
    Garganese, M. C.
    Cannata, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S87 - S87
  • [3] Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm
    Bober, Barbara
    Saracyn, Marek
    Lubas, Arkadiusz
    Kolodziej, Maciej
    Brodowska-Kania, Dorota
    Kapusta, Waldemar
    Kaminski, Grzegorz
    NUCLEAR MEDICINE REVIEW, 2022, 25 (01) : 54 - 61
  • [4] Comparison of 90-Yttrium, 177-Lutetium and 131-Iodine labeled anti aFR Mov18 for radioimmunotherapy of ovarian carcinomas
    Bombardieri, E.
    Coliva, A.
    Luison, E.
    Figini, M.
    Seregni, E.
    Zacchetti, A.
    Canevari, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S194 - S194
  • [5] Toxicity, Response and Survival Analyses of Peptide Receptor Radionuclide Therapy (PRRT) in Treatment Refractory Metastatic Thyroid Cancer Using Yttrium-90 and Lutetium-177 Labeled Somatostatin Analogs
    Prasad, V
    Budiawan, H.
    Ali, S.
    Hoersch, D.
    Zachert, C.
    Baum, R. P.
    NEUROENDOCRINOLOGY, 2010, 92 (01) : 52 - 53
  • [6] Peptide receptor radionuclide therapy (PRRT) of treatment-refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 labeled somatostatin analogs: Toxicity, response and survival analysis
    Prasad, Vikas
    Budiawan, Hendra
    Salavati, Ali
    Hoersch, Dieter
    Zachert, C.
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [7] Lutetium-177 Dotatate peptide receptor radionuclide therapy outcomes for neuroendocrine tumours
    AlHilali, M.
    Carberry, J.
    Challis, A.
    Atherton, P.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1095 - S1096
  • [8] Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
    Hoersch, D.
    Prasad, V.
    Baum, R. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues
    Ratnayake, G. M.
    Koffas, A.
    Theocharopoulos, I
    Hayes, A.
    Navalkissoor, S.
    Gnanasegaran, G.
    Quigley, A. M.
    Khoo, B.
    Mandair, D.
    Grossman, A.
    Caplin, M.
    Alsadik, S.
    Clark, R.
    Toumpanakis, C.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 157 - 157
  • [10] Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis
    Budiawan, Hendra
    Salavati, Ali
    Kulkarni, Harshad R.
    Baum, Richard P.
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 4 (01): : 39 - 52
12345